Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q1 2021 · 10-Q
Revenue$4.65M$4.65M−36.0% vs Q1 2020 Net Income-$20.38M-$20.38MN/M vs Q1 2020 EPS Diluted-$0.60-$0.60N/M vs Q1 2020 Operating Income-$20,199,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
Free Cash Flowderived-$26,017,000N/M Margins · derivedOperating margin-434.3%−356.4 pt vs Q1 2020
Net margin-438.1%−370.4 pt vs Q1 2020
ended Mar 31, 2021 · filed May 13, 2021 · 43 d after period end